Vitamin D and bone loss in HIV

Area of Science:

• Bone metabolism and endocrine health in HIV patients.
• Nutritional impacts on bone density and integrity.

Background:

• Bone health is critical for HIV-infected individuals, with high rates of osteopenia and osteoporosis.
• Antiretroviral therapy (ART) initiation is linked to significant bone loss.
• Vitamin D deficiency is prevalent in the HIV population and impacts bone health.

Purpose of the Study:

• To review the epidemiology of vitamin D deficiency in HIV.
• To summarize the relationship between vitamin D and bone loss in HIV.
• To assess the impact of vitamin D supplementation in HIV patients.

Main Methods:

• Literature review of studies on vitamin D, bone health, and HIV.
• Analysis of epidemiological data on vitamin D deficiency in HIV.
• Evaluation of randomized clinical trials on vitamin D supplementation.

Main Results:

• HIV patients may be at increased risk for vitamin D deficiency.
• Limited studies link vitamin D deficiency directly to bone loss in HIV.
• Supplementation shows potential benefits for preventing bone loss with ART and treating bone loss with bisphosphonates.

Conclusions:

• Universal vitamin D screening and supplementation for all HIV patients are not recommended due to limited data.
• Consider testing 25-hydroxyvitamin D levels in at-risk HIV patients.
• Treating vitamin D deficiency in HIV patients initiating ART or bisphosphonates is advisable; further research on immune benefits is needed.